Form 4: Bicara Therapeutics Chief Legal Officer Exercises and Sells Shares Under Pre-Arranged 10b5-1 Plan

Bicara Therapeutics Inc.'s Chief Legal Officer, Lara Meisner, exercised stock options and subsequently sold 15,829 shares of common stock for a weighted average price of $10.43 per share, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Lara Meisner, Chief Legal Officer of Bicara Therapeutics Inc. (BCAX), engaged in a series of transactions on June 16, 2025.
• She exercised stock options to acquire 15,829 shares of common stock at an exercise price of $5.45 per share.
• Immediately following the exercise, she sold all 15,829 shares of common stock at a weighted average price of $10.43 per share.
• The sales price for the common stock ranged from $10.03 to $10.84 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan that was adopted on November 13, 2024.
• After these reported transactions, Lara Meisner directly owns 0 shares of Bicara Therapeutics common stock.
• She continues to hold 60,854 stock options from one grant and 97,443 stock options from another grant, totaling 158,297 unexercised options, both with an exercise price of $5.45 and an expiration date of December 10, 2033.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale can sometimes be viewed negatively, this was a pre-planned exercise and sell transaction (common for equity compensation) and indicates the stock price was above the exercise price, allowing the insider to realize a gain. It doesn't suggest a negative outlook on the company's future, but rather personal financial planning.

Positives

• The transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a planned and compliant approach to managing equity compensation.
• The sale price of $10.43 per share is significantly higher than the exercise price of $5.45, indicating a profitable transaction for the insider.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake, although this is a common practice for managing vested equity compensation.

Future Outlook

This Form 4 filing details past transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's equity compensation management.

Comparison to Industry Standards

• As a routine insider transaction report, this document does not contain information suitable for comparison to industry-specific financial benchmarks or project results.
• The transaction itself, an exercise and sell, is a common practice for executives managing their equity compensation and realizing gains from vested stock options.

Stakeholder Impact

• Shareholders: The sale by a Chief Legal Officer could be interpreted in various ways, but given it's a 10b5-1 plan, it's generally seen as a routine management of equity compensation rather than a signal of lack of confidence. The transaction itself does not directly impact company operations or financial health.

Key Dates

Recommendation

Keywords

Bicara Therapeutics, BCAX, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Lara Meisner, Chief Legal Officer, Equity Sales, Beneficial Ownership